NeoGraph Analytics
PharmaceuticalsGlobal2026 – 2032

Sterile Injectables Market Size, Share & Forecast 2026-2032

Generic sterile injectables at $51.3B in 2026 reaching $93.39B by 2032 at 10.5% CAGR. Published sizings differ 13.6x; suppliers disclose 12.1% of the total.

Revenue, 2026

$51.3B

Forecast, 2032

$93.4B

CAGR, 2026-2032

10.5%

Report Coverage

Global

Code: sterile-injectables-marketPublished: 2026Pages: 150+Format: PDF + Excel
01

Executive Summary

Published sizings of the sterile injectables market for 2025 range from $46.43 billion to $632.46 billion. A 13.6x spread normally signals a forecasting disagreement; here it signals a scope collision, and the proof is that one publisher holds both ends. Coherent Market Insights sizes generic sterile injectables at $46.43 billion for 2025 and all sterile injectables at $586.1 billion for 2024, figures that are internally consistent because generics are roughly 7.9% of all injectable drug revenue in a category whose highest-revenue products - checkpoint inhibitors, GLP-1 receptor agonists, autoimmune biologics - are all on patent. The supplier disclosures decide which reading describes the supply business. Fresenius Kabi's Pharma division reported EUR 3,735 million for 2025 and Hikma disclosed Injectables core revenue of $1,423 million; at the IRS 2025 yearly average euro rate that is $5.64 billion in total, which is 12.1% of the generic reading and 0.95% of the $591 billion reading. Two of the largest generic sterile injectable suppliers in the world cannot be under one percent of their own market. We therefore publish the generic reading, explicitly scoped: $51.30 billion for 2026 to $93.39 billion by 2032 at 10.5%, which is the publisher's own series advanced one year on its own rate. The restraint the forecasts omit is visible in Hikma's own disclosure: Injectables core operating margin fell from 36.3% to 30.0% between the first halves of 2024 and 2025 while segment revenue grew about 12%. Sterile injectables were about 71% of all active US shortages at the end of 2025 for exactly that reason.

02

Key Highlights

1

Published 2025 sizings run $46.43 billion to $632.46 billion, a 13.6x spread caused by two scopes sharing one name, with the same publisher holding both ends

2

Fresenius Kabi Pharma EUR 3,735 million plus Hikma Injectables $1,423 million equals $5.64 billion for 2025 - 12.1% of the generic reading, 0.95% of the $591 billion reading

3

Hikma's Injectables core operating margin fell from 36.3% to 30.0% between the first halves of 2024 and 2025 while segment revenue grew about 12%, which is the shortage mechanism in one disclosure

4

Sterile injectables were about 71% of all active US shortages at the end of 2025, and all five of the longest-running US shortages, each over a decade old, are injectable medicines

5

The three public shortage registers disagree by 2.44x for overlapping periods: FDA 93, USP 75, ASHP with the University of Utah 227

6

Coherent Market Insights' generic series is the only one in this batch whose published base, endpoint and CAGR reconcile to two decimal places: 46.43 x 1.105^7 = 93.39

03

Market Overview

Market Context

Sterile injectables sit at the junction of two systems that work in opposite directions. On the demand side, the hospital and oncology formulary is increasingly parenteral, because biologics, checkpoint inhibitors and incretin agonists are injectable by construction - that is the system producing the $591 billion drug-revenue figure. On the supply side, the plants that make the off-patent injectable workhorses of anaesthesia, anti-infective and oncology care are paid tender prices against a fixed aseptic cost base - that is the system producing the $46 billion supply figure and the 71% shortage concentration. The two are usually reported as one market, which is why policy debate about shortages keeps colliding with market research that shows the category growing healthily. Both are true at once: injectable drug revenue is growing because the branded pipeline is injectable, and injectable supply is fragile because tender pricing does not fund redundancy. No published series separates them, and nothing in the 2025-2026 record suggests the procurement mechanism that produces the fragility is changing.

Published sizings of the sterile injectables market for 2025 run from $46.43 billion to $632.46 billion, a 13.6x spread - the widest in this corpus. It is not a disagreement. It is two different quantities sharing one name, and the same publisher holds both ends: Coherent Market Insights puts generic sterile injectables at $46.43 billion for 2025 and all sterile injectables at $586.1 billion for 2024. The supplier disclosures settle which is which. Fresenius Kabi's Pharma division reported EUR 3,735 million for 2025 and Hikma's Injectables segment $1,423 million; at the IRS 2025 average rate that is $5.64 billion, or 12.1% of the generic reading and 0.95% of the $591 billion reading. Two of the largest generic sterile injectable suppliers in the world cannot be under one percent of their own market. We publish the generic reading, scoped explicitly, and name the whole-injectable-drug figure as what it is.

Market Stage

Mature

Adoption Level

Universal in hospital and oncology care; supply, not demand, is the constraint

Key Trends

The 13.6x spread in published sizings is a scope collision, not a forecasting disagreement: $591 billion to $632 billion measures injectable medicines at list price, including checkpoint inhibitors and GLP-1 receptor agonists, while $46.43 billion measures the generic supply businessDisclosed supplier revenue settles the scope question: Fresenius Kabi Pharma EUR 3,735 million plus Hikma Injectables $1,423 million equals $5.64 billion for 2025, which is 12.1% of the generic reading and 0.95% of the whole-drug readingGeneric sterile injectables remain the shortage category: sterile injectables were about 71% of all active US shortages at the end of 2025, and all five of the longest-running US shortages, each over a decade old, are injectable medicinesThe three public shortage registers disagree by 2.44x for overlapping periods - FDA 93 ongoing at 31 December 2025, USP 75 at year-end 2025, ASHP with the University of Utah 227 active in Q2 2026 - because ASHP counts every drug short from a pharmacist's point of viewThe tender economics are visible in one supplier's own disclosure: Hikma's Injectables core operating margin fell from 36.3% to 30.0% between the first halves of 2024 and 2025 while segment revenue grew about 12%Currency translation is doing real work in reported growth: Fresenius Kabi's Pharma revenue fell from EUR 3,835 million to EUR 3,735 million on FX while organic growth was positive at 2%
04

Market Forecast & Data

Market Growth Forecast
2026-2032 · CAGR 10.5%

Base Year (2026)

$51.3B

Forecast (2032)

$93.4B

CAGR (2026-2032)

10.5%

Market size by year, 2026-2032, in USD Billion.
YearMarket size ($ Billion)
2026Base year$51.30B
2027$56.69B
2028$62.64B
2029$69.22B
2030$76.48B
2031$84.51B
2032$93.39B
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. Modelled at constant CAGR between published endpoints. How these figures are produced.
Forecast Analysis

The 10.5% rate published here is Coherent Market Insights' own, and it is arithmetically the cleanest series in this batch: 46.43 x 1.105^7 = 93.39 against a published 93.39, so the base, the endpoint and the rate reconcile to two decimal places. Advanced one year, 46.43 x 1.105 = 51.30 for 2026, and 51.30 x 1.105^6 = 93.39 for 2032. The gap between this 10.5% and the 7.5% to 7.9% published for the whole injectable drug market is itself informative and in the expected direction: a generic category grows faster than the branded market it erodes, because each loss of exclusivity moves revenue from the branded column to the generic one. What the rate does not price is the margin trajectory. The only supplier that publishes segment margin disclosed a 6.3-point decline on roughly 12% revenue growth, and the same company's full-year statement acknowledged challenges in the business and guided to increased investment in it. A 10.5% revenue CAGR is therefore compatible with a supply base that is getting less, not more, able to fund redundant capacity - and the shortage registers, whatever count is used, are rising rather than falling.

05

Market Dynamics

  • Biologic and oncology pipelines are injectable by construction, so the hospital injectable formulary grows with every new parenteral approval regardless of the generic supply picture
  • Loss of exclusivity on large injectable brands continuously refills the generic sterile injectable opportunity set, which is the mechanism behind the 10.5% growth rate published for the generic reading against 7.5% for the whole drug market
  • Portfolio acquisition is the fastest route to injectable scale: Hikma attributed part of its 7% Injectables growth in 2025 to the Xellia portfolio alongside new launches
  • Geographic expansion outside North America is where the growth is concentrated: Hikma reported Europe and Rest of World Injectables revenue up 23% in 2025 against North America up 5%
  • Shortage mitigation policy has made supply reliability a procurement criterion rather than purely a price one, which gives suppliers with redundant aseptic capacity a commercial reason to hold it
06

Market Segmentation

By Type

  • Small Molecule Generic Injectables
  • Complex and Long-Acting Injectables
  • Biosimilar Injectables
  • Large Volume Parenterals and IV Fluids

By End User

  • Hospital Pharmacies
  • Oncology Clinics and Infusion Centres
  • Group Purchasing Organisations
  • Government and Public Health Procurement

By Application

  • Oncology
  • Anaesthesia and Critical Care
  • Anti-Infectives
  • Cardiovascular
  • Analgesia
07

Competitive Landscape

F

Fresenius Kabi

Bad Homburg, Germany

Largest disclosed injectable-drug segment revenue in the set. Its Pharma division, reported as IV Drugs & Fluids, recorded EUR 3,735 million for 2025, equivalent to $4,215 million at the IRS 2025 average euro rate. Share is not disclosed.

Reports generic injectable drugs together with large-volume parenterals, clinical nutrition and infusion solutions, so the EUR 3,735 million figure is wider than generic sterile injectables alone. Revenue fell from EUR 3,835 million in 2024 on currency translation while organic growth was 2%, which the company attributed to solid volume demand against a strong prior-year base and disciplined pricing in Europe. Fourth-quarter 2025 Fresenius Kabi revenue of EUR 2,214 million was the highest quarter in the company's history.

H

Hikma Pharmaceuticals

London, United Kingdom

The only major supplier that discloses an Injectables segment outright: core revenue of $1,423 million for 2025, up 7% from $1,324 million, or roughly 42% of its own group revenue. Share of the wider market is not disclosed.

The most informative public disclosure in this market, because it publishes both segment revenue and segment margin. Injectables revenue grew 7% in 2025, with North America up 5% and Europe and Rest of World up 23%, helped by the Xellia portfolio and new launches. Its half-year disclosure showed the segment's core operating margin falling from 36.3% to 30.0% on about 12% revenue growth, and the chief executive acknowledged at the full year that the Injectables business had experienced challenges, with 2026 guidance assuming increased investment in it.

P

Pfizer (Hospital / Injectables)

New York, New York, United States

One of the largest generic sterile injectable suppliers in the world by portfolio breadth, built substantially on the Hospira acquisition. Injectables revenue is not reported as a standalone segment, so it cannot be added to the disclosed sum or converted into a share.

Carries a wide hospital injectable portfolio across anaesthesia, anti-infectives and oncology, and is a recurring name on US shortage notices for that reason - breadth of portfolio and breadth of shortage exposure are the same thing in this market. Because Pfizer reports injectables inside wider commercial segments, the supply side of this market cannot be summed from public filings beyond Fresenius Kabi and Hikma.

B

Baxter International

Deerfield, Illinois, United States

Major supplier of IV fluids, premixed injectables and infusion systems in the US. Injectable pharmaceuticals revenue is reported within wider segments rather than as a sterile injectables line.

Occupies the large-volume parenteral and premix end of the category, where the product is low-priced, high-volume and physically bulky, which makes it the part of the market most exposed to single-site manufacturing risk. The 2024 disruption to US IV fluid supply demonstrated how concentrated this part of the chain is, and it is a category that the branded-drug readings of this market do not represent at all.

S

Sandoz

Basel, Switzerland

Carries both a generic injectable portfolio and one of the largest biosimilar franchises, which places it across the boundary between the two readings of this market. No injectables-only share or revenue line is disclosed.

Its biosimilar business is the clearest illustration of why the generic and whole-drug readings of this market cannot be reconciled: a biosimilar injectable is priced against a generic benchmark, manufactured to biologics standards and counted in different places by different publishers. Sandoz does not disclose a sterile injectables segment, so it contributes nothing checkable to a supply-side sum.

08

Recent Developments

26
2026Hikma Pharmaceuticals

Reported 2025 full-year results on 26 February 2026: Injectables core revenue of $1,423 million, up 7% from $1,324 million, with North America up 5% and Europe and Rest of World up 23%; group revenue of $3,349 million, up 7%; statutory operating profit down 11% to $542 million; and 2026 guidance assuming increased investment in Injectables.

26
2026Fresenius Kabi

Reported full-year 2025 Pharma (IV Drugs & Fluids) revenue of EUR 3,735 million against EUR 3,835 million in 2024, the decline attributed mainly to currency translation with organic growth of 2% driven by volume demand and disciplined pricing in Europe; fourth-quarter Fresenius Kabi revenue of EUR 2,214 million was the highest quarter in company history.

26
2026American Society of Health-System Pharmacists

Reported 227 active national drug shortages with the University of Utah Drug Information Service in the second quarter of 2026, the third consecutive quarterly increase after a 2025 low, against 93 ongoing shortages in the FDA database at 31 December 2025 and 75 in USP's year-end 2025 count - a 2.44x gap between the highest and lowest public counts of the same phenomenon.

25
2025Hikma Pharmaceuticals

Interim results on 7 August 2025 disclosed Injectables revenue up about 12% while the segment's core operating margin fell to 30.0% from 36.3% a year earlier, attributed to product and geographic mix and to euro appreciation raising costs - the clearest public evidence of margin compression in the generic sterile injectable supply business.

25
2025Coherent Market Insights

Published a generic sterile injectables market of $46.43 billion for 2025 rising to $93.39 billion by 2032 at 10.5%, on 3 October 2025, against the same house's earlier whole-market figure of $586.1 billion for 2024 - the two readings of this market put side by side by a single publisher.

09

Regulatory Landscape

FDA Drug Shortages Database and the mandatory discontinuation and interruption notifications under section 506C of the Federal Food, Drug, and Cosmetic Act: manufacturers must notify FDA of a permanent discontinuance or interruption in manufacturing of certain drugs, which is the statutory basis for the 93 ongoing shortages recorded at 31 December 2025 and the reason the FDA count is narrower than ASHP's.EU GMP Annex 1 on the manufacture of sterile medicinal products, revised with effect from August 2023, which raised expectations on contamination control strategy, barrier technology and aseptic process simulation, and is a direct cost input into the aseptic lines that supply this market.FDA abbreviated new drug application review and the priority review of shortage-related applications: GAO found in GAO-16-595 that most FDA priority reviews of shortage-related applications were for generic sterile injectable drugs, establishing the category's concentration in shortages as a long-standing structural feature.USP General Chapters 797 and 800 on compounded sterile preparations and hazardous drugs, which govern how hospital pharmacies may compound around a shortage and therefore set the limits on substitution when a presentation is withdrawn.Group purchasing organisation contracting and Medicare Part B average sales price reimbursement for provider-administered injectables, which together set the price a generic sterile injectable supplier can realise and are the mechanism behind the disclosed margin compression at the one supplier that publishes segment margin.
10

Research Methodology

Primary research

  • Summation and conversion of disclosed 2025 injectable segment revenue for the two major suppliers that report it, tested against both published readings of the market
  • Comparison of the three public US drug shortage registers for overlapping periods, and identification of the definitional reason they diverge by 2.44x

Secondary research

  • Fresenius SE Annual Report 2025, results of operations - Fresenius Kabi Pharma (IV Drugs & Fluids) revenue EUR 3,735 million for 2025 against EUR 3,835 million in 2024, organic growth 2%, MedTech EUR 1,610 million
  • Hikma Pharmaceuticals plc 2025 Full Year Results, published 26 February 2026 - Injectables core revenue $1,423 million (2024: $1,324 million), +7%; group revenue $3,349 million; statutory operating profit down 11% to $542 million
  • Hikma Pharmaceuticals plc 2025 Interim Results, 7 August 2025 - Injectables core operating margin 30.0% against 36.3% in H1 2024 on approximately 12% revenue growth
  • Coherent Market Insights, generic sterile injectables market, published 3 October 2025 via BioSpace - $46.43 billion (2025) to $93.39 billion (2032) at 10.5%
  • Persistence Market Research, Sterile Injectable Drugs Market Size, Share, and Growth Forecast 2025-2032, report 122017, published September 2025 - $591.4 billion (2025) to $981.2 billion (2032) at 7.5%
  • US drug shortage counts: FDA Drug Shortages Database, 93 ongoing shortages at 31 December 2025; USP, 75 at year-end 2025 against 98 in 2024; ASHP with the University of Utah Drug Information Service, 227 active national shortages in Q2 2026; sterile injectables approximately 71% of active US shortages at end-2025 (read from a 2026 compilation, not the registers directly)
  • US Government Accountability Office, GAO-16-595, on the concentration of shortage-related priority reviews in generic sterile injectable drugs
  • IRS Yearly Average Currency Exchange Rates, 2025 annual averages, retrieved 16 October 2026 (EUR 0.886 per US dollar)

Validation: The headline was chosen by testing both published readings of this market against disclosed supplier revenue rather than against another forecast. Fresenius Kabi's Pharma division reported EUR 3,735 million for 2025, which at the IRS 2025 yearly average rate of EUR 0.886 per US dollar is $4,215 million, and Hikma disclosed Injectables core revenue of $1,423 million, for a total of $5,638 million. That is 12.1% of Coherent Market Insights' $46.43 billion generic sterile injectables market and 0.95% of Persistence Market Research's $591.4 billion sterile injectable drugs market. Two of the largest generic sterile injectable suppliers in the world cannot be under one percent of their own market, so the $591 billion series is the revenue of injectable medicines at list price - it includes branded biologics and GLP-1 receptor agonists - and not a measure of the sterile injectable supply business. The same publisher holds both ends of the 13.6x spread, which confirms the readings are additive scopes rather than rival estimates: generic at $46.43 billion is 7.9% of all sterile injectable drug revenue, which is what a category whose highest-revenue products are all on patent would be expected to show. A second check used the shortage registers: FDA recorded 93 ongoing shortages at 31 December 2025, USP 75 at year-end 2025 and ASHP with the University of Utah 227 active in Q2 2026, a 2.44x gap explained by ASHP counting every drug short from a pharmacist's point of view. These are plausibility and scope tests, not market estimates. They establish which published series measures the supply business and they do not establish its correct size; the supplier sum is also wider than the scope in one case, because Fresenius Kabi's division includes large-volume parenterals and clinical nutrition.

11

Strategic Takeaways

Before using any sterile injectables market figure, establish whether it counts injectable drug revenue at list price or the generic supply business

the two differ by roughly 13x and are published under the same name

Test any size claim in this category against the two disclosed segments - Fresenius Kabi Pharma and Hikma Injectables, $5.64 billion combined for 2025 - because a claim that makes them under 1% of their own market is measuring something else

Treat the shortage count as a definitional choice, not a fact

FDA says 93, USP 75 and ASHP 227 for overlapping periods, and the number you cite determines the conclusion you reach

Hikma's margin disclosure is the most useful public number in this market

a 6.3-point fall on growing volume is the economics that converts a tender win into a future shortage

A growing revenue CAGR in this category is not evidence of a healthy supply base; it is partly a measure of how much branded injectable revenue has fallen off patent into the generic column

12

Frequently Asked Questions

Reports in the same field, each with its base-year figure and the growth rate it is published at.